Form 4: Addex Therapeutics Director Receives Stock Grant

Sentiment:

Insider Transaction (Form 4)


Vincent Michael Lawton, a Director of Addex Therapeutics Ltd., reported multiple transactions in common stock on September 2, 2026.

Summary

  • Disposition to the issuer: disposed of 2,507,487 Common Stock on September 2, 2026; holds 500 after (Direct).
  • Grant/award: acquired 2,507,487 Common Stock on September 2, 2026; holds 2,507,987 after (Direct).
  • Disposition to the issuer: disposed of 501,598 Stock-option (Right to Buy) on September 2, 2026 (Direct).
  • Grant/award: acquired 501,598 Stock-option (Right to Buy) on September 2, 2026; holds 501,598 after (Direct).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.

Insider Transactions

Vincent Michael Lawton — Director

DateTransactionSecuritySharesPriceValueHeld After
2026-09-02Disposition to the issuerCommon Stock2,507,487——500
2026-09-02Grant/awardCommon Stock2,507,487——2,507,987
2026-09-02Disposition to the issuerStock-option (Right to Buy)501,598——0
2026-09-02Grant/awardStock-option (Right to Buy)501,598——501,598

Key Dates

DateDescription
2026-09-02Disposition to the issuer (2,507,487 shares)
2026-09-02Grant/award (2,507,487 shares)
2026-09-02Disposition to the issuer (501,598 shares)
2026-09-02Grant/award (501,598 shares)

Keywords

insider transaction, Form 4, ADXN, Addex Therapeutics Ltd., neutral, Vincent Michael Lawton

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.